Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

16 September 2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® ..

12 September 2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted..

9 September 2022

BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT..

Press releases (more)

Upcoming Events

November 7, 2022 at 8:00 AM EST

November 7, 2022: Third Quarter 2022 Earnings

November 15 - November 17, 2022

Jefferies 2022 London Healthcare Conference


November 29 - December 1, 2022

Evercore ISI’s HealthCONx Conference


Upcoming events (more)

Stock Quote

Sep 26, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.